Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 26;16(9):842-845.
doi: 10.4252/wjsc.v16.i9.842.

Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions

Yu-Xin Jin  1 , Hang-Qi Hu  1 , Jia-Cheng Zhang  1 , Xi-Yan Xin  1 , Yu-Tian Zhu  1 , Yang Ye  2 , Dong Li  1
Affiliations

Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions

Yu-Xin Jin et al. World J Stem Cells. .

Abstract

Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in liver cells and involves immune system activation, leading to histological changes, tissue damage, and clinical symptoms. A recent publication by Jiang et al, highlighted the potential of MSCs to mitigate in NAFLD progression by targeting various molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. In this editorial, we comment on their research and discuss the efficacy of MSC therapy in treating NAFLD.

Keywords: Immune cells; Liver regeneration; Mesenchymal stem cells; Non-alcoholic fatty liver disease; Therapeutic strategy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Similar articles

See all similar articles

References

    1. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14:996–1006. - PubMed
    1. Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88–110. - PubMed
    1. Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013;34:446–452. - PubMed
    1. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54:1297–1306. - PubMed
    1. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–910. - PubMed

LinkOut - more resources